News
COLL
36.48
+5.01%
1.74
Weekly Report: what happened at COLL last week (0415-0419)?
Weekly Report · 1d ago
Weekly Report: what happened at COLL last week (0408-0412)?
Weekly Report · 04/15 09:25
Commit To Purchase Collegium Pharmaceutical At $17.50, Earn 6.7% Annualized Using Options
NASDAQ · 04/12 15:35
Critical Insights From Collegium Pharmaceutical Analyst Ratings: What You Need To Know
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is developing abuse-deterrent products for the treatment of chronic pain and other diseases. Collegium Pharmaceutical has a 12-month price target of $39.75. The average price target is 7.43% higher than the previous average. 4 analysts have shared their evaluations of the company in the recent three months.
Benzinga · 04/11 13:00
Collegium Pharmaceutical to redeem outstanding 2.625% convertible senior notes due 2026
Healthcare Collegium Pharmaceutical to redeem outstanding 2.625% convertible senior notes due 2026 on June 14. The redemption price would be about $1,008.68 for each of the $26.35M aggregate principal amount of notes called for redemption. Collegium is a subsidiary of ETCollegium.
Seeking Alpha · 04/11 12:53
COLLEGIUM PHARMACEUTICAL, INC. ANNOUNCES REDEMPTION OF OUTSTANDING 2.625% CONVERTIBLE SENIOR NOTES DUE 2026
Reuters · 04/11 12:00
COLLEGIUM PHARMACEUTICAL INC: HAS CALLED ALL $26.35 MLN AGGREGATE PRINCIPAL AMOUNT OF ITS OUTSTANDING 2.625% CONVERTIBLE SENIOR NOTES DUE 2026
Reuters · 04/11 12:00
Optimistic Buy Rating for Collegium Pharmaceutical: Growth and Market Position Analysis
TipRanks · 04/11 09:48
Weekly Report: what happened at COLL last week (0401-0405)?
Weekly Report · 04/08 09:26
Weekly Report: what happened at COLL last week (0325-0329)?
Weekly Report · 04/01 09:26
Collegium Pharmaceutical (NASDAQ:COLL) shareholder returns have been stellar, earning 154% in 5 years
Collegium Pharmaceutical, Inc. Stock is up 154% over the last five years. The stock has added US$63m to its market cap in the last week alone. The company moved from a loss to profitability in the same period. Collegium Pharmaceutical shareholders have received a total shareholder return of 65% The company's share price is up 67% in the past three years.
Simply Wall St · 03/27 10:03
Weekly Report: what happened at COLL last week (0318-0322)?
Weekly Report · 03/25 09:27
Humana (HUM), DUOS Unveil Program to Improve Veterans' Health
NASDAQ · 03/21 17:39
IXJ: Healthcare Sector Dashboard For March
IShares Global Healthcare ETF is overvalued by about 13% relative to 11-year averages. Healthcare equipment has the worst value and quality scores. The healthcare sector is the most overvalued in the U.S. In March 2024. This monthly article series shows a dashboard with aggregate industry metrics in healthcare.
Seeking Alpha · 03/18 18:07
Zacks.com featured highlights AppLovin, Kaiser Aluminum, Collegium Pharmaceutical, EMCOR Group and Textron
NASDAQ · 03/18 11:46
Strength Seen in Aquestive Therapeutics (AQST): Can Its 16.0% Jump Turn into More Strength?
NASDAQ · 03/18 10:46
Weekly Report: what happened at COLL last week (0311-0315)?
Weekly Report · 03/18 09:26
Time to Get These 5 Top Relative Price Strength Stocks
NASDAQ · 03/15 10:39
3 Reasons Why Collegium Pharmaceutical (COLL) Is a Great Growth Stock
NASDAQ · 03/13 16:45
Top 10 Small-Cap Stocks (SA Quant)
S&P 500 is up 28% compared to the S&P Small-Cap index in the last 52 weeks. Small-cap stocks present enticing prospects for growth and value for investors. 10 SA Quant 'Strong Buy' rated small-Cap stocks with solid momentum and growth potential.
Seeking Alpha · 03/12 09:00
More
Webull provides a variety of real-time COLL stock news. You can receive the latest news about Collegium Pharmaceutical Inc through multiple platforms. This information may help you make smarter investment decisions.
About COLL
Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.